0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Circulating Tumor Cells- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Published Date: August 2025
|
Report Code: QYRE-Auto-37Y9103
Home | Market Reports | Health| Health Conditions| Cancer
Global Circulating Tumor Cells Market Insights and Forecast to 2028
BUY CHAPTERS

Circulating Tumor Cells- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-37Y9103
Report
August 2025
Pages:137
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Circulating Tumor Cells- Market Size

The global market for Circulating Tumor Cells was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.

Circulating Tumor Cells- Market

Circulating Tumor Cells- Market

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen(Adnagen), Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells by region & country, by Type, and by Application.
The Circulating Tumor Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells.
Market Segmentation

Scope of Circulating Tumor Cells- Market Report

Report Metric Details
Report Name Circulating Tumor Cells- Market
Forecasted market size in 2031 US$ 8259 million
CAGR 20.4%
Forecasted years 2025 - 2031
Segment by Type
  • CTC Enrichment
  • CTC Detection
  • CTC Analysis
Segment by Application
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Menarini-Silicon Biosystems, Qiagen (Adnagen), Advanced Cell Diagnostics, ApoCell, Epic Sciences, Greiner Bio-one GmbH, Cynvenio, SurExamBio-Tech, Fluxion Biosciences, Ikonisys, Hangzhou Watson Biotech, Biocept, CytoTrack, Guangzhou Wondfo Biotech, Celsee, Clearbridge Biomedics, ANGLE plc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Circulating Tumor Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Circulating Tumor Cells in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Circulating Tumor Cells- Market size in 2031?

Ans: The Circulating Tumor Cells- Market size in 2031 will be US$ 8259 million.

What is the market share of major companies in Circulating Tumor Cells- Market?

Ans: Global top five manufacturers hold a share over 30%.

Who are the main players in the Circulating Tumor Cells- Market report?

Ans: The main players in the Circulating Tumor Cells- Market are Menarini-Silicon Biosystems, Qiagen (Adnagen), Advanced Cell Diagnostics, ApoCell, Epic Sciences, Greiner Bio-one GmbH, Cynvenio, SurExamBio-Tech, Fluxion Biosciences, Ikonisys, Hangzhou Watson Biotech, Biocept, CytoTrack, Guangzhou Wondfo Biotech, Celsee, Clearbridge Biomedics, ANGLE plc

What are the Application segmentation covered in the Circulating Tumor Cells- Market report?

Ans: The Applications covered in the Circulating Tumor Cells- Market report are Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Others

What are the Type segmentation covered in the Circulating Tumor Cells- Market report?

Ans: The Types covered in the Circulating Tumor Cells- Market report are CTC Enrichment, CTC Detection, CTC Analysis

1 Market Overview
1.1 Circulating Tumor Cells Product Introduction
1.2 Global Circulating Tumor Cells Market Size Forecast (2020-2031)
1.3 Circulating Tumor Cells Market Trends & Drivers
1.3.1 Circulating Tumor Cells Industry Trends
1.3.2 Circulating Tumor Cells Market Drivers & Opportunity
1.3.3 Circulating Tumor Cells Market Challenges
1.3.4 Circulating Tumor Cells Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Circulating Tumor Cells Players Revenue Ranking (2024)
2.2 Global Circulating Tumor Cells Revenue by Company (2020-2025)
2.3 Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters
2.4 Key Companies Circulating Tumor Cells Product Offered
2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells
2.6 Circulating Tumor Cells Market Competitive Analysis
2.6.1 Circulating Tumor Cells Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CTC Enrichment
3.1.2 CTC Detection
3.1.3 CTC Analysis
3.2 Global Circulating Tumor Cells Sales Value by Type
3.2.1 Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Circulating Tumor Cells Sales Value, by Type (2020-2031)
3.2.3 Global Circulating Tumor Cells Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Breast Cancer
4.1.2 Prostate Cancer
4.1.3 Colorectal Cancer
4.1.4 Lung Cancer
4.1.5 Others
4.2 Global Circulating Tumor Cells Sales Value by Application
4.2.1 Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Circulating Tumor Cells Sales Value, by Application (2020-2031)
4.2.3 Global Circulating Tumor Cells Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Circulating Tumor Cells Sales Value by Region
5.1.1 Global Circulating Tumor Cells Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Circulating Tumor Cells Sales Value by Region (2020-2025)
5.1.3 Global Circulating Tumor Cells Sales Value by Region (2026-2031)
5.1.4 Global Circulating Tumor Cells Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Circulating Tumor Cells Sales Value, 2020-2031
5.2.2 North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Circulating Tumor Cells Sales Value, 2020-2031
5.3.2 Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Circulating Tumor Cells Sales Value, 2020-2031
5.4.2 Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Circulating Tumor Cells Sales Value, 2020-2031
5.5.2 South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Circulating Tumor Cells Sales Value, 2020-2031
5.6.2 Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Circulating Tumor Cells Sales Value, 2020-2031
6.3 United States
6.3.1 United States Circulating Tumor Cells Sales Value, 2020-2031
6.3.2 United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Circulating Tumor Cells Sales Value, 2020-2031
6.4.2 Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Circulating Tumor Cells Sales Value, 2020-2031
6.5.2 China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.5.3 China Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Circulating Tumor Cells Sales Value, 2020-2031
6.6.2 Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Circulating Tumor Cells Sales Value, 2020-2031
6.7.2 South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Circulating Tumor Cells Sales Value, 2020-2031
6.8.2 Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Circulating Tumor Cells Sales Value, 2020-2031
6.9.2 India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
6.9.3 India Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Menarini-Silicon Biosystems
7.1.1 Menarini-Silicon Biosystems Profile
7.1.2 Menarini-Silicon Biosystems Main Business
7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions
7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.1.5 Menarini-Silicon Biosystems Recent Developments
7.2 Qiagen (Adnagen)
7.2.1 Qiagen (Adnagen) Profile
7.2.2 Qiagen (Adnagen) Main Business
7.2.3 Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions
7.2.4 Qiagen (Adnagen) Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.2.5 Qiagen (Adnagen) Recent Developments
7.3 Advanced Cell Diagnostics
7.3.1 Advanced Cell Diagnostics Profile
7.3.2 Advanced Cell Diagnostics Main Business
7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions
7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.3.5 Advanced Cell Diagnostics Recent Developments
7.4 ApoCell
7.4.1 ApoCell Profile
7.4.2 ApoCell Main Business
7.4.3 ApoCell Circulating Tumor Cells Products, Services and Solutions
7.4.4 ApoCell Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.4.5 ApoCell Recent Developments
7.5 Epic Sciences
7.5.1 Epic Sciences Profile
7.5.2 Epic Sciences Main Business
7.5.3 Epic Sciences Circulating Tumor Cells Products, Services and Solutions
7.5.4 Epic Sciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.5.5 Epic Sciences Recent Developments
7.6 Greiner Bio-one GmbH
7.6.1 Greiner Bio-one GmbH Profile
7.6.2 Greiner Bio-one GmbH Main Business
7.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions
7.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.6.5 Greiner Bio-one GmbH Recent Developments
7.7 Cynvenio
7.7.1 Cynvenio Profile
7.7.2 Cynvenio Main Business
7.7.3 Cynvenio Circulating Tumor Cells Products, Services and Solutions
7.7.4 Cynvenio Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.7.5 Cynvenio Recent Developments
7.8 SurExamBio-Tech
7.8.1 SurExamBio-Tech Profile
7.8.2 SurExamBio-Tech Main Business
7.8.3 SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions
7.8.4 SurExamBio-Tech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.8.5 SurExamBio-Tech Recent Developments
7.9 Fluxion Biosciences
7.9.1 Fluxion Biosciences Profile
7.9.2 Fluxion Biosciences Main Business
7.9.3 Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions
7.9.4 Fluxion Biosciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.9.5 Fluxion Biosciences Recent Developments
7.10 Ikonisys
7.10.1 Ikonisys Profile
7.10.2 Ikonisys Main Business
7.10.3 Ikonisys Circulating Tumor Cells Products, Services and Solutions
7.10.4 Ikonisys Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.10.5 Ikonisys Recent Developments
7.11 Hangzhou Watson Biotech
7.11.1 Hangzhou Watson Biotech Profile
7.11.2 Hangzhou Watson Biotech Main Business
7.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions
7.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.11.5 Hangzhou Watson Biotech Recent Developments
7.12 Biocept
7.12.1 Biocept Profile
7.12.2 Biocept Main Business
7.12.3 Biocept Circulating Tumor Cells Products, Services and Solutions
7.12.4 Biocept Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.12.5 Biocept Recent Developments
7.13 CytoTrack
7.13.1 CytoTrack Profile
7.13.2 CytoTrack Main Business
7.13.3 CytoTrack Circulating Tumor Cells Products, Services and Solutions
7.13.4 CytoTrack Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.13.5 CytoTrack Recent Developments
7.14 Guangzhou Wondfo Biotech
7.14.1 Guangzhou Wondfo Biotech Profile
7.14.2 Guangzhou Wondfo Biotech Main Business
7.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions
7.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.14.5 Guangzhou Wondfo Biotech Recent Developments
7.15 Celsee
7.15.1 Celsee Profile
7.15.2 Celsee Main Business
7.15.3 Celsee Circulating Tumor Cells Products, Services and Solutions
7.15.4 Celsee Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.15.5 Celsee Recent Developments
7.16 Clearbridge Biomedics
7.16.1 Clearbridge Biomedics Profile
7.16.2 Clearbridge Biomedics Main Business
7.16.3 Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions
7.16.4 Clearbridge Biomedics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.16.5 Clearbridge Biomedics Recent Developments
7.17 ANGLE plc
7.17.1 ANGLE plc Profile
7.17.2 ANGLE plc Main Business
7.17.3 ANGLE plc Circulating Tumor Cells Products, Services and Solutions
7.17.4 ANGLE plc Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
7.17.5 ANGLE plc Recent Developments
8 Industry Chain Analysis
8.1 Circulating Tumor Cells Industrial Chain
8.2 Circulating Tumor Cells Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Circulating Tumor Cells Sales Model
8.5.2 Sales Channel
8.5.3 Circulating Tumor Cells Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
 Table 1. Circulating Tumor Cells Market Trends
 Table 2. Circulating Tumor Cells Market Drivers & Opportunity
 Table 3. Circulating Tumor Cells Market Challenges
 Table 4. Circulating Tumor Cells Market Restraints
 Table 5. Global Circulating Tumor Cells Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Circulating Tumor Cells Revenue Market Share by Company (2020-2025)
 Table 7. Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Circulating Tumor Cells Product Type
 Table 9. Key Companies Time to Begin Mass Production of Circulating Tumor Cells
 Table 10. Global Circulating Tumor Cells Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Circulating Tumor Cells Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 14. Global Circulating Tumor Cells Sales Value by Type (2020-2025) & (US$ Million)
 Table 15. Global Circulating Tumor Cells Sales Value by Type (2026-2031) & (US$ Million)
 Table 16. Global Circulating Tumor Cells Sales Market Share in Value by Type (2020-2025)
 Table 17. Global Circulating Tumor Cells Sales Market Share in Value by Type (2026-2031)
 Table 18. Global Circulating Tumor Cells Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 19. Global Circulating Tumor Cells Sales Value by Application (2020-2025) & (US$ Million)
 Table 20. Global Circulating Tumor Cells Sales Value by Application (2026-2031) & (US$ Million)
 Table 21. Global Circulating Tumor Cells Sales Market Share in Value by Application (2020-2025)
 Table 22. Global Circulating Tumor Cells Sales Market Share in Value by Application (2026-2031)
 Table 23. Global Circulating Tumor Cells Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 24. Global Circulating Tumor Cells Sales Value by Region (2020-2025) & (US$ Million)
 Table 25. Global Circulating Tumor Cells Sales Value by Region (2026-2031) & (US$ Million)
 Table 26. Global Circulating Tumor Cells Sales Value by Region (2020-2025) & (%)
 Table 27. Global Circulating Tumor Cells Sales Value by Region (2026-2031) & (%)
 Table 28. Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 29. Key Countries/Regions Circulating Tumor Cells Sales Value, (2020-2025) & (US$ Million)
 Table 30. Key Countries/Regions Circulating Tumor Cells Sales Value, (2026-2031) & (US$ Million)
 Table 31. Menarini-Silicon Biosystems Basic Information List
 Table 32. Menarini-Silicon Biosystems Description and Business Overview
 Table 33. Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Circulating Tumor Cells Business of Menarini-Silicon Biosystems (2020-2025)
 Table 35. Menarini-Silicon Biosystems Recent Developments
 Table 36. Qiagen (Adnagen) Basic Information List
 Table 37. Qiagen (Adnagen) Description and Business Overview
 Table 38. Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Circulating Tumor Cells Business of Qiagen (Adnagen) (2020-2025)
 Table 40. Qiagen (Adnagen) Recent Developments
 Table 41. Advanced Cell Diagnostics Basic Information List
 Table 42. Advanced Cell Diagnostics Description and Business Overview
 Table 43. Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Circulating Tumor Cells Business of Advanced Cell Diagnostics (2020-2025)
 Table 45. Advanced Cell Diagnostics Recent Developments
 Table 46. ApoCell Basic Information List
 Table 47. ApoCell Description and Business Overview
 Table 48. ApoCell Circulating Tumor Cells Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Circulating Tumor Cells Business of ApoCell (2020-2025)
 Table 50. ApoCell Recent Developments
 Table 51. Epic Sciences Basic Information List
 Table 52. Epic Sciences Description and Business Overview
 Table 53. Epic Sciences Circulating Tumor Cells Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Circulating Tumor Cells Business of Epic Sciences (2020-2025)
 Table 55. Epic Sciences Recent Developments
 Table 56. Greiner Bio-one GmbH Basic Information List
 Table 57. Greiner Bio-one GmbH Description and Business Overview
 Table 58. Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Circulating Tumor Cells Business of Greiner Bio-one GmbH (2020-2025)
 Table 60. Greiner Bio-one GmbH Recent Developments
 Table 61. Cynvenio Basic Information List
 Table 62. Cynvenio Description and Business Overview
 Table 63. Cynvenio Circulating Tumor Cells Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Circulating Tumor Cells Business of Cynvenio (2020-2025)
 Table 65. Cynvenio Recent Developments
 Table 66. SurExamBio-Tech Basic Information List
 Table 67. SurExamBio-Tech Description and Business Overview
 Table 68. SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Circulating Tumor Cells Business of SurExamBio-Tech (2020-2025)
 Table 70. SurExamBio-Tech Recent Developments
 Table 71. Fluxion Biosciences Basic Information List
 Table 72. Fluxion Biosciences Description and Business Overview
 Table 73. Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Circulating Tumor Cells Business of Fluxion Biosciences (2020-2025)
 Table 75. Fluxion Biosciences Recent Developments
 Table 76. Ikonisys Basic Information List
 Table 77. Ikonisys Description and Business Overview
 Table 78. Ikonisys Circulating Tumor Cells Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Circulating Tumor Cells Business of Ikonisys (2020-2025)
 Table 80. Ikonisys Recent Developments
 Table 81. Hangzhou Watson Biotech Basic Information List
 Table 82. Hangzhou Watson Biotech Description and Business Overview
 Table 83. Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions
 Table 84. Revenue (US$ Million) in Circulating Tumor Cells Business of Hangzhou Watson Biotech (2020-2025)
 Table 85. Hangzhou Watson Biotech Recent Developments
 Table 86. Biocept Basic Information List
 Table 87. Biocept Description and Business Overview
 Table 88. Biocept Circulating Tumor Cells Products, Services and Solutions
 Table 89. Revenue (US$ Million) in Circulating Tumor Cells Business of Biocept (2020-2025)
 Table 90. Biocept Recent Developments
 Table 91. CytoTrack Basic Information List
 Table 92. CytoTrack Description and Business Overview
 Table 93. CytoTrack Circulating Tumor Cells Products, Services and Solutions
 Table 94. Revenue (US$ Million) in Circulating Tumor Cells Business of CytoTrack (2020-2025)
 Table 95. CytoTrack Recent Developments
 Table 96. Guangzhou Wondfo Biotech Basic Information List
 Table 97. Guangzhou Wondfo Biotech Description and Business Overview
 Table 98. Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions
 Table 99. Revenue (US$ Million) in Circulating Tumor Cells Business of Guangzhou Wondfo Biotech (2020-2025)
 Table 100. Guangzhou Wondfo Biotech Recent Developments
 Table 101. Celsee Basic Information List
 Table 102. Celsee Description and Business Overview
 Table 103. Celsee Circulating Tumor Cells Products, Services and Solutions
 Table 104. Revenue (US$ Million) in Circulating Tumor Cells Business of Celsee (2020-2025)
 Table 105. Celsee Recent Developments
 Table 106. Clearbridge Biomedics Basic Information List
 Table 107. Clearbridge Biomedics Description and Business Overview
 Table 108. Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions
 Table 109. Revenue (US$ Million) in Circulating Tumor Cells Business of Clearbridge Biomedics (2020-2025)
 Table 110. Clearbridge Biomedics Recent Developments
 Table 111. ANGLE plc Basic Information List
 Table 112. ANGLE plc Description and Business Overview
 Table 113. ANGLE plc Circulating Tumor Cells Products, Services and Solutions
 Table 114. Revenue (US$ Million) in Circulating Tumor Cells Business of ANGLE plc (2020-2025)
 Table 115. ANGLE plc Recent Developments
 Table 116. Key Raw Materials Lists
 Table 117. Raw Materials Key Suppliers Lists
 Table 118. Circulating Tumor Cells Downstream Customers
 Table 119. Circulating Tumor Cells Distributors List
 Table 120. Research Programs/Design for This Report
 Table 121. Key Data Information from Secondary Sources
 Table 122. Key Data Information from Primary Sources
 Table 123. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Circulating Tumor Cells Product Picture
 Figure 2. Global Circulating Tumor Cells Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Circulating Tumor Cells Sales Value (2020-2031) & (US$ Million)
 Figure 4. Circulating Tumor Cells Report Years Considered
 Figure 5. Global Circulating Tumor Cells Players Revenue Ranking (2024) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Circulating Tumor Cells Revenue in 2024
 Figure 7. Circulating Tumor Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 8. CTC Enrichment Picture
 Figure 9. CTC Detection Picture
 Figure 10. CTC Analysis Picture
 Figure 11. Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 12. Global Circulating Tumor Cells Sales Value Market Share by Type, 2024 & 2031
 Figure 13. Product Picture of Breast Cancer
 Figure 14. Product Picture of Prostate Cancer
 Figure 15. Product Picture of Colorectal Cancer
 Figure 16. Product Picture of Lung Cancer
 Figure 17. Product Picture of Others
 Figure 18. Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 19. Global Circulating Tumor Cells Sales Value Market Share by Application, 2024 & 2031
 Figure 20. North America Circulating Tumor Cells Sales Value (2020-2031) & (US$ Million)
 Figure 21. North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
 Figure 22. Europe Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 23. Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
 Figure 24. Asia Pacific Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 25. Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031
 Figure 26. South America Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 27. South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
 Figure 28. Middle East & Africa Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 29. Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
 Figure 30. Key Countries/Regions Circulating Tumor Cells Sales Value (%), (2020-2031)
 Figure 31. United States Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 32. United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 33. United States Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 34. Europe Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 35. Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 36. Europe Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 37. China Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 38. China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 39. China Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 40. Japan Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 41. Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 42. Japan Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 43. South Korea Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 44. South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 45. South Korea Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 46. Southeast Asia Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 47. Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 48. Southeast Asia Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 49. India Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
 Figure 50. India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
 Figure 51. India Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
 Figure 52. Circulating Tumor Cells Industrial Chain
 Figure 53. Circulating Tumor Cells Manufacturing Cost Structure
 Figure 54. Channels of Distribution (Direct Sales, and Distribution)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart